Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03708367 · ClinicalTrials.gov registry record · NA
A Post-Market Evaluation of LipiFlow Treatment in Cataract Surgery Practice
A NA study of Cataracts and Meibomian Gland Dysfunction (MGD), sponsored by Johnson & Johnson Surgical Vision.
- Completed
- Registry status
- NA
- Development phase
- 117
- Enrollment target
- 5
- Study locations
NCT03708367 is a NA study of Cataracts and Meibomian Gland Dysfunction (MGD) that has completed, run by Johnson & Johnson Surgical Vision. The registered enrollment target is 117 participants, above the 83-participant average among 8 other Cataracts trials with a reported enrollment target (41% higher). The trial reports 5 study locations across 4 states.
The verdict
NCT03708367, a NA study of Cataracts and Meibomian Gland Dysfunction (MGD), has completed, sponsored by Johnson & Johnson Surgical Vision.
- COMPLETED
- Registry status
- NA
- Development phase
- 117 participants
- Enrollment target
- 5
- Study locations
Study Summary
This is a post-market, prospective, randomized, multi-center, bilateral, open-label, cross-over, comparative clinical study. Study group will undergo preoperative LipiFlow treatment and Control group will not receive preoperative LipiFlow treatment. Three months postoperatively, both groups will be evaluated for clinical outcomes and the Control group will receive LipiFlow treatment as the cross-over group. The Control group will be evaluated at 4 months postoperative for clinical outcomes.
Conditions Studied
Interventions
- DEVICE LipiFlow Thermal Pulsation System
Study Locations (5)
Texas
- JW Eye Associates, P.A. - Dallas
- Texas Eye & Laser Center, P.A. - Hurst
California
- Empire Eye & Laser Center, Inc. - Bakersfield
Maryland
- Eye Doctors of Washington - Chevy Chase
New Jersey
- Matossian Eye Associates - Pennington
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 117 participants |
| Start Date | 2018-10-16 |
| Est. Completion | 2020-01-13 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03708367
The ClinicalTrials.gov registry entry for NCT03708367 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 117 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 83-participant average among 8 other Cataracts trials with a reported enrollment target (41% higher). The listed sponsor is Johnson & Johnson Surgical Vision, which has 22 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Cataracts appearing as the primary indexed condition, and to 1 intervention - of which LipiFlow Thermal Pulsation System is the first listed.
NCT03708367 reports 5 study locations spanning 4 distinct geographic areas - top geographies include Texas, California, Maryland.
Frequently Asked Questions
What is clinical trial NCT03708367 about?
NCT03708367 is a clinical study titled "A Post-Market Evaluation of LipiFlow Treatment in Cataract Surgery Practice". This is a post-market, prospective, randomized, multi-center, bilateral, open-label, cross-over, comparative clinical study. Study group will undergo preoperative LipiFlow treatment and Control group will not receive preoperative LipiFlow treatment. Three months postoperatively, both groups will be ...
What is the current status of trial NCT03708367?
This trial is currently completed. It is a NA study. The enrollment target is 117 participants. The study started on 2018-10-16. Estimated completion is 2020-01-13.
What conditions does trial NCT03708367 study?
This clinical trial studies the following conditions: Cataracts, Meibomian Gland Dysfunction (MGD).
What interventions are being tested in trial NCT03708367?
The interventions under investigation include: LipiFlow Thermal Pulsation System (DEVICE).
Who is sponsoring clinical trial NCT03708367?
This trial is sponsored by Johnson & Johnson Surgical Vision, which has 22 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03708367 being conducted?
This trial has 5 study locations across California, Maryland, New Jersey, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cataracts
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Intraocular Pressure Control Following One Site Versus Two Site Combined Phacoemulsification/IOL And Trabeculectomy
COMPLETED · NA
-
Determination of Optimum Duration of Treatment With Bromfenac (Xibrom) Eyedrops Following Cataract Surgery
COMPLETED · Phase 4
-
Dispervise Ophthalmic Viscoelastic as an Agent to Ensure Watertight Wound Closure After Clear Corneal Cataract Incisions
COMPLETED · Phase 4
-
Clear Corneal Incisions and Arcuate Incisions Utilizing FemtoSecond Laser Technology for Cataract Surgery
COMPLETED · Phase 4
-
Aqueous Absorption and Pharmacokinetics of Besivance Versus VIGAMOX in Patients Undergoing Phacoemulsification
COMPLETED · Phase 4
-
DisCoVisc Comparative Evaluation
COMPLETED · Phase 3
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.